$ETNB
89bio, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022019927 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.259M $4.610M
YoY Change 14.08% 57.88%
% of Gross Profit
Research & Development $19.85M $10.13M
YoY Change 95.92% 30.25%
% of Gross Profit
Depreciation & Amortization $18.00K $15.00K
YoY Change 20.0% 25.0%
% of Gross Profit
Operating Expenses $19.85M $14.74M
YoY Change 34.67% 37.72%
Operating Profit -$25.11M -$14.74M
YoY Change 70.35% 37.72%
Interest Expense $408.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$456.0K -$43.00K
YoY Change 960.47% -127.39%
Pretax Income -$25.56M -$14.78M
YoY Change 72.94% 40.18%
Income Tax $1.000K $0.00
% Of Pretax Income
Net Earnings -$25.57M -$14.78M
YoY Change 72.95% 40.19%
Net Earnings / Revenue
Basic Earnings Per Share -$1.26
Diluted Earnings Per Share -$1.257M -$738.6K
COMMON SHARES
Basic Shares Outstanding 20.34M
Diluted Shares Outstanding 20.34M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $126.1M $189.6M
YoY Change -33.5% 121.75%
Cash & Equivalents $54.89M $68.01M
Short-Term Investments $71.20M $121.6M
Other Short-Term Assets $9.323M $8.300M
YoY Change 12.33% 336.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $135.4M $197.9M
YoY Change -31.58% 126.43%
LONG-TERM ASSETS
Property, Plant & Equipment $138.0K $200.0K
YoY Change -31.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $218.0K $600.0K
YoY Change -63.67% 733.33%
Total Long-Term Assets $356.0K $800.0K
YoY Change -55.5% 176.82%
TOTAL ASSETS
Total Short-Term Assets $135.4M $197.9M
Total Long-Term Assets $356.0K $800.0K
Total Assets $135.8M $198.7M
YoY Change -31.67% 126.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.421M $4.500M
YoY Change -1.76% 10.97%
Accrued Expenses $8.979M $3.900M
YoY Change 130.23% 4.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M
YoY Change
Total Short-Term Liabilities $18.40M $8.500M
YoY Change 116.47% 9.16%
LONG-TERM LIABILITIES
Long-Term Debt $14.47M $0.00
YoY Change
Other Long-Term Liabilities $151.0K
YoY Change
Total Long-Term Liabilities $14.47M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $18.40M $8.500M
Total Long-Term Liabilities $14.47M $0.00
Total Liabilities $33.02M $8.500M
YoY Change 288.52% 8.97%
SHAREHOLDERS EQUITY
Retained Earnings -$238.8M -$137.9M
YoY Change 73.18% 63.87%
Common Stock $341.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $102.7M $190.2M
YoY Change
Total Liabilities & Shareholders Equity $135.8M $198.7M
YoY Change -31.66% 126.54%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$25.57M -$14.78M
YoY Change 72.95% 40.19%
Depreciation, Depletion And Amortization $18.00K $15.00K
YoY Change 20.0% 25.0%
Cash From Operating Activities -$24.34M -$14.98M
YoY Change 62.49% 93.27%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $4.000K
YoY Change 50.0% -93.44%
Acquisitions
YoY Change
Other Investing Activities $26.78M -$15.41M
YoY Change -273.77%
Cash From Investing Activities $26.77M -$15.41M
YoY Change -273.73% 25162.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.00K 216.0K
YoY Change -86.57% 2300.0%
NET CHANGE
Cash From Operating Activities -24.34M -14.98M
Cash From Investing Activities 26.77M -15.41M
Cash From Financing Activities 29.00K 216.0K
Net Change In Cash 2.457M -30.18M
YoY Change -108.14% 286.67%
FREE CASH FLOW
Cash From Operating Activities -$24.34M -$14.98M
Capital Expenditures $6.000K $4.000K
Free Cash Flow -$24.35M -$14.99M
YoY Change 62.48% 91.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-30
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.906
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.975
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.007
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.910
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.976
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.008
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238782000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213217000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
102741000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5000000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14473000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16898000
CY2022Q1 etnb Other Non Current Liability
OtherNonCurrentLiability
151000
CY2021Q4 etnb Other Non Current Liability
OtherNonCurrentLiability
30000
CY2022Q1 us-gaap Liabilities
Liabilities
33024000
CY2021Q4 us-gaap Liabilities
Liabilities
36465000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
341759000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339218000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-256000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135765000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162422000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19849000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10131000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4608000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25565000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14782000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-195000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-4000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-192000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25757000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14775000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2512000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25565000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
216000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1793000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14782000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25565000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14782000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2512000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1793000
CY2022Q1 etnb Accretion Of Final Payment Fee
AccretionOfFinalPaymentFee
121000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-118000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-229000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
77000
CY2022Q1 us-gaap Depreciation
Depreciation
18000
CY2021Q1 us-gaap Depreciation
Depreciation
15000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1942000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2726000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-72000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-72000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2422000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2450000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1215000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2110000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24344000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14982000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
36179000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
29896000
CY2022Q1 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
9401000
CY2021Q1 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
45302000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26772000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15410000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
29000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
216000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
216000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2457000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30176000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p>
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98208000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54914000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68032000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54889000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68007000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54914000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68032000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
169000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
154000
CY2021Q1 etnb Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
6000
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
126100000
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2022Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
0
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
110152000
CY2022Q1 etnb Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
1714000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111866000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
120726000
CY2021Q4 etnb Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
5277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126003000
CY2022Q1 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
6201000
CY2021Q4 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
7895000
CY2022Q1 us-gaap Prepaid Taxes
PrepaidTaxes
831000
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
836000
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2266000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2506000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9298000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11237000
CY2022Q1 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6495000
CY2021Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6195000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1562000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3168000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
613000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
495000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
309000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
336000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8979000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10194000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
150000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
7000
CY2022Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
157000
CY2022Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
69000
CY2021Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
73000
CY2022Q1 etnb Percentage Of Fee On Loan
PercentageOfFeeOnLoan
0.05
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2500000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10000000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7500000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
527000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
19473000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5000000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14473000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2512000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1793000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3835732
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2395195

Files In Submission

Name View Source Status
0001564590-22-019927-index-headers.html Edgar Link pending
0001564590-22-019927-index.html Edgar Link pending
0001564590-22-019927.txt Edgar Link pending
0001564590-22-019927-xbrl.zip Edgar Link pending
etnb-10q_20220331.htm Edgar Link pending
etnb-10q_20220331_htm.xml Edgar Link completed
etnb-20220331.xsd Edgar Link pending
etnb-20220331_cal.xml Edgar Link unprocessable
etnb-20220331_def.xml Edgar Link unprocessable
etnb-20220331_lab.xml Edgar Link unprocessable
etnb-20220331_pre.xml Edgar Link unprocessable
etnb-ex311_7.htm Edgar Link pending
etnb-ex312_8.htm Edgar Link pending
etnb-ex32_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending